About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four clinical trials for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer and medullary thyroid cancer, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com .
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-march-300414648.html
SOURCE Blueprint Medicines